Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab in Systemic Sclerosis
NCT04683029Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2021
- Primary completion
- May 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of guselkumab in diffuse cutaneous systemic sclerosis (dcSSc), sponsored by Janssen Pharmaceutical. Started Feb 2021; status: completed.
02
Drugs
guselkumab
03
Conditions
diffuse cutaneous systemic sclerosis (dcSSc)
Beyond the preview
Go deeper on NCT04683029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04683029.